» Articles » PMID: 36400532

Sickle Cell Disease Pathophysiology and Related Molecular and Biophysical Biomarkers

Overview
Specialties Hematology
Oncology
Date 2022 Nov 18
PMID 36400532
Authors
Affiliations
Soon will be listed here.
Abstract

One of the challenges in sickle cell disease is its clinical variability. Our ability to identify the complications that a patient is at risk for is limited by a lack of validated diagnostic and prognostic biomarkers. Clinical care is limited by a lack of diagnostics to capture the biological variability needed to precisely direct patient care. Many biomarkers have been proposed, but few validated. We must make a concerted effort as a field to rigorously test proposed biomarkers to improve outcomes for our patients.

Citing Articles

Non-invasive optical and laboratory hematologic biomarkers correlate in patients with sickle cell disease.

Quang T, Mostashari G, Berning E, Gopalan B, Lizarralde-Iragorri M, Lovins D Biomed Opt Express. 2024; 15(8):4829-4841.

PMID: 39346999 PMC: 11427197. DOI: 10.1364/BOE.527770.


Multidisciplinary approaches to study anaemia with special mention on aplastic anaemia (Review).

Sankar D, Oviya I Int J Mol Med. 2024; 54(5).

PMID: 39219286 PMC: 11410310. DOI: 10.3892/ijmm.2024.5419.


Hemoglobin scavenger receptor CD163 as a potential biomarker of hemolysis-induced hepatobiliary injury in sickle cell disease.

Kaminski T, Sivanantham A, Mozhenkova A, Smith A, Ungalara R, Dubey R Am J Physiol Cell Physiol. 2024; 327(2):C423-C437.

PMID: 38682236 PMC: 11427010. DOI: 10.1152/ajpcell.00386.2023.


Lactate dehydrogenase and hemolysis index to predict vaso-occlusive crisis in sickle cell disease.

Feugray G, Dumesnil C, Grall M, Benhamou Y, Girot H, Fettig J Sci Rep. 2023; 13(1):21198.

PMID: 38040880 PMC: 10692321. DOI: 10.1038/s41598-023-48324-w.